7/27/2019 Case Pres Drug Analysis

1/6

DRUG ANALYSIS

NAME OF THE DRUG MODE OF ACTION INDICATIONS/CONTRAINDICATIONS

SIDE/ADVERSEEFFECTS

NURSINGRESPONSIBILITIES

Generic Name:Vancocin

Brand Name:Vancomycin

Classification:

Therapeutic: Anti-infectives

Route and Dosage:IV (Adults): 1 cpm q12

Binds to bacterial cell wall,resulting in cell death

Indication: (IV)-Staphylococcal infections-Soft-tissue infections in

patients who have allergiesto penicillin or itsderivatives or when

sensitivity testingdemonstrates resistance tomethicillin

Contraindication:-Hypersensitivity

EENT: ototoxicity

CV: hypotension

GI: nausea andvomiting

GU: nephrotoxicity

Derm: rashes

Hemat: eosinophilia,leucopenia

Local: Phlebitis

MS: back and neck

pain

Misc:hypersensitivityreactions includinganaphylaxis, chills,fever, superinfection

-Assess patient for infection (v/s, appearanceof wound, sputum, urine,and stool; WBC) at

beginning of andthroughout therapy-Obtain specimens for

culture and sensitivity prior to initiating therapy-Monitor IV site closely.Vancomycin is irritatingto tissues and causesnecrosis and severe painwith extravasation.Rotate infusion site-Monitor blood pressurethroughout IV infusion

-Monitor intake andoutput ratios and dailyweight. Cloudy or pink urine may be a sign of nephrotoxicity-Assess patient for signsof superinfection (black,furry overgrowth ontongue; loose or foul-smelling stools)

7/27/2019 Case Pres Drug Analysis

2/6

-Observe patient for anysigns of anaphylaxis(rash, pruritus, laryngealedema)

Lab Test Considerations:-Monitor for casts,albumin, or cells in theurine or decreasedspecific gravity, CBC,and renal function

periodically duringtherapy-May cause increasedBUN levels

7/27/2019 Case Pres Drug Analysis

3/6

NAME OF THE DRUG MODE OF ACTION INDICATIONS/

CONTRAINDICATIONSSIDE/ADVERSE

EFFECTS NURSING

RESPONSIBILITIES

Generic Name:Primaxin

Brand Name:Imipenem/Cilastatin

Classification:Therapeutic: Anti-infectives

Pharmacologic:carbapenems

Route and Dosage:IV (Adults): 500 mg q6

Binds to the bacterial cellwall, resulting in cell death.Combination with cilastatin

prevents renal inactivation of imipenem, resulting in highurinary concentrations.Imipenem resists the actionsof many enzymes thatdegrade most other

penicillins and penicillin-likeanti-infectives

Indication:-Treatment of skin and skin structureinfections

Contraindication:-Hypersensitivity-Cross-sensitivity mayoccur with pencillins and

cephalosporins

CNS: seizures,dizziness,

CV: hypotension

GI: pseudomembranousdiarrhea, nausea,vomiting

Derm: rash, pruritus,sweating, uticaria

Hemat: eosinophilia

Local: Phlebitis atIV site

Misc: allergicreaction includinganaphylaxis, fever,

superinfection

-Assess patient for infection (v/s, appearanceof wound, sputum, urine,and stool; WBC) at

beginning of andthroughout therapy-Obtain history beforeinitiating therapy todetermine previous useof and reactions to

penicillin-Obtain specimens for culture and sensitivity

prior to initiating therapy-Assess patient for signsof superinfection (black,furry overgrowth ontongue; loose or foul-smelling stools)-Observe patient for anysigns of anaphylaxis

(rash, pruritus, laryngealedema)

Lab Test Considerations:-Monitor for BUN, AST,ALT, LDH, serumalkaline phosphatise,

bilirubin, and creatininemay be transientlyincrease

7/27/2019 Case Pres Drug Analysis

4/6

-hemoglobin andhematocritconcentrations may bedecreased-May cause positivedirect Coombs test

7/27/2019 Case Pres Drug Analysis

5/6

7/27/2019 Case Pres Drug Analysis

6/6

muscle cramps,hyperhidrosis

effect may not be seenfor 4 hr. Do notadminister second doseuntil BP has beenchecked.